Inspite of immense progress achieved in the field of percutaneous coronary interventions (PCIs), treatment of diffuse long atherosclerotic coronary artery disease continues to remain a challenge for durable outcomes. The downstream reduction in diameter along the lesion length of a coronary artery may compel the cardiologist to use either two overlapping stents of different diameters or a single long stent leading to stent-vessel mismatch at the edges. Recently Meril Life Sciences Pvt. Ltd., India has introduced a long-tapered sirolimus-eluting stent (SES) system, BioMime Morph which conforms to the normal tapered geometry of coronary arteries along with adequate lesion coverage. The aim of the present study was to provide the real world experience regarding the safety and efficacy of the BioMime Morph SES over a follow-up of one year.
This was a single centre, retrospective study involving 172 participants who underwent PCI with BioMime Morph SES. Mean length of the target lesion was 34.4±10.4 mm and mean stent length was 53.2±8.7 mm. Most frequent revascularized vessel was left anterior descending artery (LAD) in 97 lesions (54.4%). Major adverse cardiac events (MACE) (defined as composite of target vessel myocardial infarction, target lesion revascularization and death due to cardiac cause) at 1, 6 and 12 months were seen in 4 (2.3%), 7(4.0%) and 8(4.7%) patients respectively. Overall, five cardiac deaths and two definite stent thrombosis were observed in the study.
The study suggests that novel BioMime Morph SES is an effective and a safe option for PCI of long diffuse atherosclerotic lesions.